Evidence map›Paper›PMID 41764075›Full record

ArticleHGG advances2026

Gene-specific pathogenicity predictor for chromatin remodeling BAF complex-associated neurodevelopmental disorders.

Joshua Hack, Mohammad Nazim

Abstract read
In one paragraph

Article in HGG advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Joshua HackGenetics and Genomics Department, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: jhack2@g.ucla.edu.
Mohammad NazimDepartment of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; Center for RNA Science and Therapeutics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA. Electronic address: mxn598@case.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advancements in whole-genome sequencing have increased the number of variants of uncertain significance (VUS) identified in human genomes. This has created a diagnostic bottleneck for genetic counselors tasked with sifting through these variants and determining those most likely to be causative for a patient's clinical presentation. Machine learning (ML) tools can aid in identifying pathogenic variants from VUS, but there is a need for gene-specific algorithms that predict pathogenic variants with high accuracy. To address this need, we present a workflow for developing gene-specific, ensemble-learning ML tools, that leverage outputs from other algorithms, locations of variants within the gene, and evolutionary conservation data to make a prediction of pathogenicity. Variants in SMARCA2 and SMARCA4 that are associated with rare neurodevelopmental diseases were used to screen 15 ML algorithms. A random forest learner was tuned to yield a final accuracy of 0.93 on holdout data. Generalizing this predictor to other BRG1/BRM-associated factor (BAF) complex proteins resulted in a sharp decline in performance. We trained a final predictor for all genes in the study to create a predictor that identifies pathogenic variants in these BAF subunits with an accuracy of 0.91 on holdout data. This predictor specific to BAF complex proteins performs with higher accuracy and area under the precision-recall curve than any other predictor. The decline in performance when generalized to other proteins emphasizes the need for the gene-specific calibration of predictors. Our workflow for the development of such models provides a quick, computationally inexpensive route for improving the ML tools available to genetic counselors.

Indexed as

Chromatin Assembly and DisassemblyDNA HelicasesGenetic Predisposition to DiseaseNeurodevelopmental DisordersNuclear ProteinsTranscription FactorsAlgorithmsHumansMachine LearningPrediction AlgorithmsPredictive Learning ModelsDNA HelicasesNuclear ProteinsSMARCA2 protein, humanSMARCA4 protein, humanTranscription Factorsdiagnosticsgenetic counselingmachine learningmonogenic diseaserare diseasevariants of uncertain significance

Identifiers

PMID41764075
PMCPMC13000492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.